Expanding treatment options for metastatic prostate cancer.
作者信息
Antonarakis Emmanuel S, Eisenberger Mario A
出版信息
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
Abstract
摘要
相似文献
1
Expanding treatment options for metastatic prostate cancer.扩大转移性前列腺癌的治疗选择。
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
2
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者生存率的提高
N Engl J Med. 2011 Aug 25;365(8):766; author reply 767-8. doi: 10.1056/NEJMc1107198.
3
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者生存率的提高
N Engl J Med. 2011 Aug 25;365(8):766-7; author reply 767-8. doi: 10.1056/NEJMc1107198.
4
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
5
Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.联合治疗：阿比特龙可延长转移性前列腺癌患者的生存时间。
Nat Rev Clin Oncol. 2011 Aug 2;8(9):515-6. doi: 10.1038/nrclinonc.2011.111.
6
Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.醋酸阿比特龙（泽珂）用于转移性去势抵抗性前列腺癌。
Med Lett Drugs Ther. 2011 Aug 25;53(1370):63-4.
7
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.新型裂解酶抑制剂对雄激素类固醇合成的选择性阻断作为治疗转移性前列腺癌的一种治疗策略。
BJU Int. 2005 Dec;96(9):1241-6. doi: 10.1111/j.1464-410X.2005.05821.x.
8
[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].[雄激素合成关键酶抑制剂：作为前列腺癌靶点的潜在药物]
Nihon Rinsho. 2000 Jul;58 Suppl:312-6.
9
Abiraterone acetate is well tolerated without concomitant use of corticosteroids.醋酸阿比特龙在不联合使用皮质类固醇的情况下耐受性良好。
J Clin Oncol. 2010 Oct 10;28(29):e560-1; author reply e562. doi: 10.1200/JCO.2010.29.5170. Epub 2010 Aug 30.
10
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.醋酸阿比特龙在前列腺癌治疗中的作用：文献的批判性分析。
Eur Urol. 2011 Aug;60(2):270-8. doi: 10.1016/j.eururo.2011.04.032. Epub 2011 Apr 29.
引用本文的文献
1
Identifying Key Genes as Progression Indicators of Prostate Cancer with Castration Resistance Based on Dynamic Network Biomarker Algorithm and Weighted Gene Correlation Network Analysis.基于动态网络生物标志物算法和加权基因共表达网络分析鉴定关键基因作为去势抵抗性前列腺癌进展的指标
Biomedicines. 2024 Sep 23;12(9):2157. doi: 10.3390/biomedicines12092157.
2
Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer.增强感染性、条件复制型腺病毒用于 COX-2 表达的去势抵抗性前列腺癌。
Viruses. 2023 Mar 31;15(4):901. doi: 10.3390/v15040901.
3
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.双相雄激素治疗继以雄激素受体抑制作为前列腺癌的序贯治疗。
Oncologist. 2023 Jun 2;28(6):465-473. doi: 10.1093/oncolo/oyad055.
4
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.靶向前列腺癌中的信号通路：机制与临床试验。
Signal Transduct Target Ther. 2022 Jun 24;7(1):198. doi: 10.1038/s41392-022-01042-7.
5
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.PI3K/Akt/mTOR信号通路抑制剂在前列腺癌化学预防和干预中的作用
Pharmaceutics. 2021 Aug 3;13(8):1195. doi: 10.3390/pharmaceutics13081195.
6
Identification of castration-resistant prostate cancer-related hub genes using weighted gene co-expression network analysis.基于加权基因共表达网络分析鉴定去势抵抗性前列腺癌相关枢纽基因。
J Cell Mol Med. 2020 Jul;24(14):8006-8017. doi: 10.1111/jcmm.15432. Epub 2020 Jun 2.
7
8
Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth in Prostate Cancer.蒲公英根提取物和柠檬草提取物可诱导前列腺癌细胞凋亡、增强化疗疗效并减少肿瘤异种移植生长。
Evid Based Complement Alternat Med. 2019 Jul 17;2019:2951428. doi: 10.1155/2019/2951428. eCollection 2019.
9
Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB.沉默中期因子可增强类黄酮芹菜素抗前列腺癌干细胞活性：ERK、p38、PTEN、PARP 和 NF-κB 信号通路调节的协同作用。
Invest New Drugs. 2020 Apr;38(2):246-263. doi: 10.1007/s10637-019-00774-8. Epub 2019 Apr 16.
10
Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.晚期前列腺癌伴错配修复基因突变患者的临床特征和治疗结局。
Eur Urol. 2019 Mar;75(3):378-382. doi: 10.1016/j.eururo.2018.10.009. Epub 2018 Oct 15.
本文引用的文献
1
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
2
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.地舒单抗对比唑来膦酸治疗去势抵抗性前列腺癌骨转移患者的随机、双盲研究。
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
3
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
4
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
5
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.饿死成瘾性：持久抑制前列腺癌中雄激素受体信号传导的新机遇。
Clin Cancer Res. 2009 Aug 1;15(15):4792-8. doi: 10.1158/1078-0432.CCR-08-2660. Epub 2009 Jul 28.
6
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.源自隐蔽外显子剪接的非配体依赖性雄激素受体变体意味着激素难治性前列腺癌。
Cancer Res. 2009 Jan 1;69(1):16-22. doi: 10.1158/0008-5472.CAN-08-2764.
7
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗
N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.
8
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.低风险前列腺癌的面貌变迁：临床表现及初始治疗的趋势
J Clin Oncol. 2004 Jun 1;22(11):2141-9. doi: 10.1200/JCO.2004.10.062.
9
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).单独使用抗雄激素药物或与酮康唑联合用于雄激素非依赖性前列腺癌患者：一项III期试验（CALGB 9583）。
J Clin Oncol. 2004 Mar 15;22(6):1025-33. doi: 10.1200/JCO.2004.06.037.
10
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.米托蒽醌联合泼尼松或单用泼尼松治疗有症状的激素抵抗性前列腺癌的化疗：一项以姑息治疗为终点的加拿大随机试验
J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756.
Zotero 插件